Results 341 to 346 of about 93,200 (346)

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Lancet, The, 2013
Iain B Mcinnes, Arthur Kavanaugh, Proton Rahman   +2 more
exaly  

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Lancet, The, 2018
Philip J Mease, Laura C Coates Mb Chb, Mykola A Stanislavchuk   +2 more
exaly  

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Lancet, The, 2018
Atul Deodhar, Mrcp, Alice B Gottlieb, Wolf-Henning Boehncke   +2 more
exaly  

The pathogenesis of psoriatic arthritis

Lancet, The, 2018
Ursula Fearon
exaly  

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Lancet, The, 2017
Peter Nash, Bruce W Kirkham, Proton Rahman   +2 more
exaly  

Clinical management of psoriatic arthritis

Lancet, The, 2018
Filip E Van Den Bosch, Laura Coates
exaly